Obermatt
See Similar Stocks →

Alembic Pharmaceuticals

NSI:APLLTD · INE901L01018
PharmaceuticalsLarge

360

51
EV / EBIT36
Price / Owner Earnings31
Owner Earnings Yield65
Dividend Yield75
Price/Sales73
EV / Gross Profit80
Price/Book64
Return on Capital75
Cash Return on Capital65
Return on Equity69
EBIT Margin44
Gross Profitability94
Cash Conversion36
Owner Earnings Margin52
Sales growth44
Profit Growth33
Long-Term EPS Growth36
Reinvestment26
Price momentum21
Debt load46
Refinancing84
Debt Payback35
Liquidity36
Analyst ratings37
Opinion Changes14
Price Target Upside20
Market mood31
Value Creation17/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Alembic Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNSEI
Founded2010
Employees7,639
Websitealembicpharmaceuticals.com
ISININE901L01018
Last UpdateApr 2, 2026
Index & Theme
OphthalmologyCardiovascularDiabetesRespiratoryDermatologyOncologyUrologyNephrologyManufacturingPharmaceutical

Description

Alembic Pharmaceuticals Limited (Alembic) is a leading Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a broad range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is…

Analysis

Middle-of-the-road

Alembic Pharmaceuticals Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 23.8×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 17/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
23
2023202420252026

All-time high

92

Jan 2024

All-time low

23

Jun 2026

Average rank

50

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
73
69
78
70
Price/Earnings
68
66
68
72
Price/Book
64
62
73
72
Dividend Yield
75
67
59
65
Value (overall)
90
75
73
77

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alembic Pharmaceuticals with its peers
Ipca Laboratories
NSI:IPCALAB
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Deepak Nitrite
NSI:DEEPAKNTR
48
CountryIndia
IndustryChemicals
SizeMedium
Full Stock Analysis →
Cipla
NSI:CIPLA
53
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Ajanta Pharma
NSI:AJANTPHARM
65
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →